Evidence map›Paper›PMID 36845614›Full record

ArticleAdvances in radiation oncology

Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery.

David J Carpenter, Andrew T Fairchild, Justus D Adamson, Peter E Fecci, John H Sampson, James E Herndon, Jordan A Torok, Trey C Mullikin, Grace J Kim, Zachary J Reitman and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

David J CarpenterDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Andrew T FairchildPiedmont Radiation Oncology, Winston-Salem, North Carolina.
Justus D AdamsonDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Peter E FecciDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
John H SampsonDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
James E HerndonDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Jordan A TorokDepartment of Radiation Oncology, St. Clair Hospital Cancer Center, Pittsburgh, Pennsylvania.
Trey C MullikinDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Grace J KimDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Zachary J ReitmanDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
John P KirkpatrickDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Scott R FloydDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Duke Medical Center · USDuke University · USPiedmont International University · USUPMC Hillman Cancer Center · US

Funding

Duke Radiation Oncology and Radiology Stimulating Access to Research in ResidencyR38CA245204 · NCI · DUKE UNIVERSITY · PI FLOYD, SCOTT R · 2020 to 2023
$1.4M
NCI NIH HHS R38 CA245204
6 · The paper itself

Abstract

Purpose: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-SRS. Methods and Materials: Patients undergoing HF-SRS for intact (iHF-SRS) or resected (rHF-SRS) BMs from 2008 to 2018 were retrospectively identified. Linear accelerator-based image-guided HF-SRS consisted of 5 fractions at 5, 5.5, or 6 Gy per fraction. Time to local progression (LP), time to distant brain progression (DBP), and overall survival (OS) were calculated. Cox models assessed effect of clinical factors on OS. Fine and Gray's cumulative incidence model for competing events examined effect of factors on LP and DBP. The occurrence of leptomeningeal disease (LMD) was determined. Logistic regression examined predictors of LMD. Results: Among 445 patients, median age was 63.5 years; 87% had Karnofsky performance status ≥70. Fifty-three % of patients underwent surgical resection, and 75% received 5 Gy per fraction. Patients with resected BMs had higher Karnofsky performance status (90-100, 41 vs 30%), less extracranial disease (absent, 25 vs 13%), and fewer BMs (multiple, 32 vs 67%). Median diameter of the dominant BM was 3.0 cm (interquartile range, 1.8-3.6 cm) for intact BMs and 4.6 cm (interquartile range, 3.9-5.5 cm) for resected BMs. Median OS was 5.1 months (95% confidence interval [CI], 4.3-6.0) following iHF-SRS and 12.8 months (95% CI, 10.8-16.2) following rHF-SRS ( Conclusions: HF-SRS demonstrated favorable rates of LC and radionecrosis in postoperative and intact settings. Corresponding LMD and RN rates were comparable to those of other studies.

Identifiers

PMID36845614
PMCPMC9943776
OpenAlexW4313368275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.